A on NYSE

Agilent Technologies

Logo: Agilent, Public domain, via Wikimedia Commons5

American technology company

Agilent Technologies, Inc. is an American global company headquartered in Santa Clara, California, that provides instruments, software, services, and consumables for laboratories. Agilent was established in 1999 as a spin-off from Hewlett-Packard. The resulting initial public offering of Agilent stock was the largest in the history of Silicon Valley at the time.3 It was founded by Bill Hewlett.1 Its chief executive is Padraig McDonnell (since 2024).1 It employed about 17,700 people in 2023.1 Its revenue was $6.8 billion in 2022.1 Its shares trade on NYSE under the symbol A.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

$6.9BRevenue, fiscal 20256
$1.3BNet income, fiscal 20256
1999Founded1

Compare with Coherent, Inc., Avantor or Illumina, or pick any stock.

  • TickerA on NYSE1
  • Industryelectronics industry, high-performance liquid chromatography, measurement tool1
  • HeadquartersSanta Clara1
  • Websitewww.agilent.com
  • Legal formS.A.1
  • Incorporated inDE7
  • Business address5301 Stevens Creek Blvd, Santa Clara, Ca 950517
  • Filer categoryLarge accelerated filer7
  • LEIQUIX8Y7A2WP0XRMW7G294
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressCORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 30385464
Agilent-HQ-Lobby
Photo: Hathaway Dinwiddie Construction Company, Attribution, via Wikimedia Commons10

Agilent Technologies, Inc. is an American global company headquartered in Santa Clara, California, that provides instruments, software, services, and consumables for laboratories. Agilent was established in 1999 as a spin-off from Hewlett-Packard. The resulting initial public offering of Agilent stock was the largest in the history of Silicon Valley at the time.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

21.3%Operating margin6
18.8%Net margin6
6.7%Revenue growth, 20256
19.3%Return on equity6
0.45×Debt to equity6
$1.2BFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Non-Instrumentation and Other brought in 65% of the revenue Agilent Technologies broke down this way in fiscal 2025.

  1. Non-Instrumentation and Other$4.5B665%up 9% from 2024
  2. Instrumentation$2.4B635%up 3% from 2024
Products and services by year
Products and services202320242025
Non-Instrumentation and Other$4.1B$4.2B$4.5B
Instrumentation$2.7B$2.4B$2.4B

Business segments

Agilent CrossLab brought in 42% of the revenue Agilent Technologies broke down this way in fiscal 2025.

  1. Agilent CrossLab$2.9B642%up 6% from 2024
  2. Life Sciences and Diagnostics Markets$2.7B639%up 11% from 2024
  3. Applied Markets$1.3B619%up 1% from 2024
Business segments by year
Business segments202320242025
Agilent CrossLab$2.7B$2.7B$2.9B
Life Sciences and Diagnostics Markets$2.8B$2.5B$2.7B
Applied Markets$1.4B$1.3B$1.3B

Regions

Rest Of World brought in 24% of the revenue Agilent Technologies broke down this way in fiscal 2025.

  1. Rest Of World$3.4B624%up 11% from 2024
  2. Americas$2.8B620%up 9% from 2024
  3. United States$2.3B617%up 4% from 2024
  4. Asia Pacific$2.2B616%up 2% from 2024
  5. Europe$1.9B614%up 9% from 2024
  6. China$1.2B69%up 1% from 2024
Regions by year
Regions202320242025
Rest Of World$3.0B$3.0B$3.4B
Americas$2.7B$2.6B$2.8B
United States$2.4B$2.2B$2.3B
Asia Pacific$2.3B$2.2B$2.2B
Europe$1.8B$1.8B$1.9B
China$1.4B$1.2B$1.2B

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue47¢$3.3B
  • Research and development6¢$455.0M
  • Selling, general and admin24¢$1.7B
  • Interest2¢$112.0M
  • Income tax2¢$132.0M
  • Profit19¢$1.3B

Out of $6.9B in revenue.6

Where each dollar of operating cash went, fiscal 2025

  • Capital spending26¢$407.0M
  • Dividends paid18¢$282.0M
  • Share buybacks27¢$425.0M
  • Kept or used elsewhere29¢$445.0M

Out of $1.6B of cash from operations.6

Financial statements

Revenue11121314156$6.9B in 2025+41% since 2018
0$2.0B$4.0B$6.0B$8.0B2018: $4.9B$4.9B20182019: $5.2B$5.2B2019+5%2020: $5.3B$5.3B2020+3%2021: $6.3B$6.3B2021+18%2022: $6.8B$6.8B2022+8%2023: $6.8B$6.8B2023−0%2024: $6.5B$6.5B2024−5%2025: $6.9B$6.9B2025+7%
Operating income11121314156$1.5B in 2025+64% since 2018
0$500.0M$1.0B$1.5B$2.0B2018: $904.0M$904.0M20182019: $941.0M$941.0M2019+4%2020: $846.0M$846.0M2020−10%2021: $1.3B$1.3B2021+59%2022: $1.6B$1.6B2022+20%2023: $1.4B$1.4B2023−17%2024: $1.5B$1.5B2024+10%2025: $1.5B$1.5B2025−1%
Net income11121314156$1.3B in 2025+312% since 2018
0$500.0M$1.0B$1.5B2018: $316.0M$316.0M20182019: $1.1B$1.1B2019+239%2020: $719.0M$719.0M2020−33%2021: $1.2B$1.2B2021+68%2022: $1.3B$1.3B2022+4%2023: $1.2B$1.2B2023−1%2024: $1.3B$1.3B2024+4%2025: $1.3B$1.3B2025+1%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-10-312024-10-312023-10-31
Net revenue$6.9B$6.5B$6.8B
Cost of revenue$3.3B$3.0B$3.4B
Research and development$455.0M$479.0M$481.0M
Selling, general and administrative$1.7B$1.6B$1.6B
Total costs and expenses$5.5B$5.0B$5.5B
Income from operations$1.5B$1.5B$1.4B
Interest income$62.0M$80.0M$51.0M
Interest expense-$112.0M-$96.0M-$95.0M
Other income (expense), net$6.0M$49.0M$33.0M
Income before taxes, as reported$1.4B$1.5B$1.3B
Provision for income taxes$132.0M$232.0M$99.0M
Net Income$1.3B$1.3B$1.2B
Net income per share - basic$4.59$4.44$4.22
Net income per share - diluted$4.57$4.43$4.19
Basic (in shares)284.0M shares290.0M shares294.0M shares
Diluted (in shares)285.0M shares291.0M shares296.0M shares

Compare Agilent Technologies with another company

Corporate structure

Agilent Technologies sits at the top of its group. 26 entities, 14 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Agilent Technologies

  • Agilent Technologies Wilmington, Delaware, United States
    • Advanced Analytical Technologies (United States) Subsidiary · Ankeny, United States
    • Agilent Technologies (United Kingdom) Subsidiary · Stockport, United Kingdom
    • BioTek (company) Subsidiary · Winooski
    • Stratagene California Subsidiary
    • Varian, Inc. Subsidiary · Palo Alto
    • Agilent Technologies (Australia) Subsidiary · Australia
    • Agilent Technologies (Germany) Subsidiary · Germany
    • Agilent Technologies (India) Subsidiary · India
    • Agilent Technologies (japan) Subsidiary · Japan
    • Agilent Technologies Canada Holding LLC Subsidiary · Canada
    • Agilent Technologies Germany Holding GmbH Subsidiary · Germany
    • Agilent Technologies Italia S.p.A. Subsidiary · Italy
    • AGILENT TECHNOLOGIES LDA MALAYSIA SDN. BHD. Subsidiary · Bayan Lepas, Malaysia
    • AGILENT TECHNOLOGIES LUXCO LLC Subsidiary · Santa Clara, California, United States
      • 한국애질런트테크놀로지스(주) Subsidiary · 100% · Seoul, South Korea
      • AGILENT TECHNOLOGIES TRADING (SHANGHAI) CO., LTD. (安捷伦科技贸易(上海)有限公司) Subsidiary · Shanghai, China
    • Agilent Technologies Netherlands B.V. Subsidiary · Netherlands
    • AGILENT TECHNOLOGIES SALES (MALAYSIA) SDN. BHD. Subsidiary · Petaling Jaya, Malaysia
    • Agilent Technologies Singapore (Global) Pte Ltd. Subsidiary · Singapore
    • AGILENT TECHNOLOGIES SINGAPORE (HOLDINGS) PTE. LTD. Subsidiary · Singapore, Singapore
    • Agilent Technologies Singapore (International) Pte. Ltd. Subsidiary · Singapore
    • Agilent Technologies Singapore Corporation Pte. Ltd. Subsidiary · Singapore
    • Agilent Technologies World Trade, Inc. Subsidiary · Delaware, United States
    • BioVectra Inc. Subsidiary · Canada
    • Dako Denmark ApS Subsidiary · Denmark

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Agilent Technologies reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Land$69.0M6 Oct 31, 2025$69.0M6 Oct 31, 20240%
Buildings and improvements$2.1B6 Oct 31, 2025$1.8B6 Oct 31, 2024+15.1%
Machinery and equipment$1.0B6 Oct 31, 2025$960.0M6 Oct 31, 2024+8.0%
Computer equipment and software$284.0M6 Oct 31, 2025$267.0M6 Oct 31, 2024+6.4%
Property and equipment, before depreciation$3.4B6 Oct 31, 2025$3.1B6 Oct 31, 2024+11.8%
Accumulated depreciation$1.4B6 Oct 31, 2025$1.3B6 Oct 31, 2024+9.1%
Property and equipment, net$2.0B6 Oct 31, 2025$1.8B6 Oct 31, 2024+13.8%
Operating-lease assets (leased space)$183.0M6 Oct 31, 2025$177.0M6 Oct 31, 2024+3.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.8B6 Oct 31, 2025$1.3B6 Oct 31, 2024+34.6%
Equity securities at fair value$06 Oct 31, 2025$06 Oct 31, 2024
Stakes in other companies (equity method)$06 Oct 31, 2025$06 Oct 31, 2024
Long-term investments$133.0M6 Oct 31, 2025$175.0M6 Oct 31, 2024−24.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$4.5B6 Oct 31, 2025$4.5B6 Oct 31, 2024−0.1%
Intangible assets, net (excluding goodwill)$445.0M6 Oct 31, 2025$547.0M6 Oct 31, 2024−18.6%
Indefinite-lived intangibles (excluding goodwill)$06 Oct 31, 2025$06 Oct 31, 2024
Finite-lived intangibles, gross$2.0B6 Oct 31, 2025$2.0B6 Oct 31, 20240%
Accumulated amortization$1.6B6 Oct 31, 2025$1.5B6 Oct 31, 2024+6.9%
Finite-lived intangibles, net$547.0M15 Oct 31, 2024$465.0M15 Oct 31, 2023+17.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$1.0B6 Oct 31, 2025$972.0M6 Oct 31, 2024+5.5%
Finished goods$547.0M6 Oct 31, 2025$523.0M6 Oct 31, 2024+4.6%

Properties, in its own words

As of October 31, 2025, we owned or leased a total of approximately 6.8 million square feet of space worldwide. Of that, we owned approximately 5.3 million square feet and leased the remaining 1.5 million square feet. Our sales and support facilities occupied a total of approximately 0.5 million square feet. Our manufacturing plants, research and development facilities and warehouse and administrative facilities occupied approximately 6.3 million square feet. All of our business segments share sales offices throughout the world.

Information about each of our businesses appears below:

The rest of Item 2

Life Sciences and Diagnostics Markets Segment. Our Life Sciences and Diagnostics Markets segment has manufacturing and research and development facilities in Belgium, Canada, China, Denmark, Germany, Malaysia, Singapore, United Kingdom and the United States.

Agilent CrossLab Segment. Our Agilent CrossLab segment has manufacturing and research and development facilities in Australia, Germany, Netherlands, Singapore, United Kingdom and the United States, and our direct service delivery organization is regionally based and operating in 28 countries.

Applied Markets Segment. Our Applied Markets segment has manufacturing and research and development facilities in Australia, China, Germany, Italy, Japan, Malaysia, Singapore, United Kingdom and the United States.

Item 2 of the 10-K filed Dec 22, 2025.20

The story

Founded by Bill Hewlett in 1999.1

In 1965, Hewlett-Packard branched out into scientific equipment by acquiring F&M Scientific, maker of gas chromatographs. Agilent Technologies was created in 1999 as a spin-off of several business units of Hewlett-Packard including test & measurement, optics, instrumentation and chemical analysis, electronic components, and medical equipment product lines. The split was predicated on the difficulty of growing HP's revenue stream and on the competitive vigor of smaller, more agile competitors.

The company's launch slogan was "Innovating the HP Way", which capitalized on the strong HP corporate culture called The HP Way. The starburst logo was selected to reflect "a burst of insight" (or "spark of insight") and the name "Agilent" aimed to invoke the notion of agility as a trait of the new firm. The Agilent spin-off was accompanied by an initial public offering which raised $2.1 billion, setting a record at the time.

2000–2009

In the early 2000s, "economic uncertainty" depressed demand for Agilent's products, including slow sales of health care products to hospitals in the United States, which accounted for 60% of the company's revenue at the time. The downturn also struck sales in the communications and semiconductor markets, where orders amounting to $500 million were canceled by buyers. These poor economic conditions prompted large reductions in force with 18,500 positions cut in 2003.

In 2001, in midst of this downsizing, Agilent sold its health care and medical products organization to Philips Medical Systems, and was noted as having a valuation of about $11 billion. HP Medical Products had been the second oldest part of Hewlett-Packard, acquired in the 1950s.

In August 2005, Agilent announced the sale of its business which produced semiconductor integrated circuits (known as "chips") for consumer and industrial uses to Kohlberg Kravis Roberts and Silver Lake Partners for $2.66 billion. This move would involve termination of about 1,300 of the company's 28,000 employees. The group operated as a private company, Avago Technologies, until August 2009, when it was brought public in an IPO. After purchasing Broadcom Corporation in 2016, Avago changed its name to Broadcom Limited.

Also in August 2005, Agilent sold its 47% stake in the light-emitting diode manufacturer Lumileds to Philips for $1 billion. Lumileds originally started as Hewlett-Packard's optoelectronics division. Also in August 2005, Agilent announced a plan to divest its semiconductor test business, composed of both the system-on-chip and memory test market areas. Agilent listed the new company as Verigy on the Nasdaq in mid-2006.

2010 onwards

In 2009, Agilent announced the closure of a subsection of its Test & Measurement division. The product lines affected included the automated optical inspection, solder paste inspection, and automated X-ray products [5DX] in 2004. In 2011, the company, along with the University of California, Davis, announced that it would be establishing the "Davis Millimeter Wave Research Center". Agilent announced it would increase its life sciences engagement through the acquisition of Halo Genomics, based in Uppsala, Sweden, which was involved in next-generation sequencing technology development. On May 17, 2012, Agilent agreed to buy Dako, a Danish cancer diagnostics company, for $2.2 billion, to expand its presence in the life sciences industry.

On September 19, 2013, Agilent announced its decision to separate into two publicly traded companies: Agilent, a life sciences, diagnostics, and applied markets company, and Keysight, an electronic measurement company. The life sciences company retained the Agilent name and the electronic measurement company was called Keysight Technologies. On October 14, 2014, the company announced that it is exiting its Nuclear Magnetic Resonance business. On November 1, the formal separation of Agilent and Keysight Technologies was completed. Agilent announced it had completed the spin-off of its electronic measurement business, Keysight Technologies.

Read the full text

In September 2015, the company announced it would acquire Seahorse Bioscience for $235 million. On July 7, 2016, Agilent announced that it had acquired U.K. based Cobalt Light Systems, which develops and manufactures Raman spectroscopy instruments, for £40 million in cash. In December the company acquired Multiplicom N.V.

In January 2018, the company announced it would acquire Luxcel Biosciences, increasing the company's cell analysis portfolio. In May, Agilent acquired Lasergen, Inc. after the end of its two-year option on a prior investment. In the same month it acquired digital laboratory management company, Genohm, Ultra Scientific, provider of chemical standards and reference materials and Advanced Analytical Technologies, Inc. (AATI), provider of capillary electrophoresis-based molecules for $250 million in cash.

In August the company announced it would acquire glycan reagent producer, ProZyme, Inc. and South Korean instrument distributor, Young In Scientific Co. Ltd. In September Agilent acquired ACEA Biosciences for $250 million increasing the company's presence in cell analysis technologies. In August 2019, Agilent acquired US-based BioTek Instruments, a designer, manufacturer, and distributor of life science instrumentation, for $1.165 billion. On May 1, 2024, Padraig McDonnell succeeded Mike McMullen as CEO.

From Wikipedia’s article on Agilent Technologies, shared under CC BY-SA 4.0.8

Leadership

Who has led Agilent Technologies, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (60)

Products and brands

  • multi-well plate
  • plate reader
  • scientific instrument
  • software

Listed on Wikidata.1

Agilent serves analytical laboratories and the clinical and routine diagnostics markets with a full suite of technology platforms. These include: automation, bioreagents, FISH probes, gas and liquid chromatography, immunohistochemistry, informatics, mass spectrometry, microarrays, spectroscopy, target enrichment, and vacuum technologies.

Agilent also provides lab management services, including enterprise asset management, laboratory business intelligence, equipment management and service, software maintenance, regulatory compliance, sample preparation, genomics and cloning, GC and HPLC columns, spectrometry and spectroscopy supplies, and consumables. The company is known for investing in R&D within its own research labs and those of leading universities to advance the state of knowledge in the life sciences, diagnostics, and chemical analysis space.

In recent years, the company has advanced digital lab instrumentation and technology that improves lab workflow and overall efficiency and productivity. In 2020, Agilent introduced CrossLab Virtual Assist, a mobile app that facilities high-quality remote technical support. Agilent's digital advancements, including CrossLab Connect, have also improved lab optimization and sustainability by providing more efficient utilization of instruments, which can lower a lab's energy consumption.

Agilent is also a pioneer of the target enrichment used as part of a NGS workflow. The portfolio also includes sample prep, QA/QC instrumentation, 2100 bioanalyzers, and automation tools. In early 2023, the company announced a $725 million expansion of its nucleic acid-based therapeutics manufacturing facility in Frederick, Colorado.

From Wikipedia’s article on Agilent Technologies, shared under CC BY-SA 4.0.8

Subsidiaries and ownership

Subsidiaries

Subsidiaries (Exhibit 21)

  • Agilent Technologies Canada Holding LLC Canada9
  • Agilent Technologies Germany Holding GmbH Germany9
  • Agilent Technologies Italia S.p.A. Italy9
  • Agilent Technologies Luxco LLC Delaware9
  • Agilent Technologies Netherlands B.V. Netherlands9
  • Agilent Technologies Singapore (Global) Pte Ltd. Singapore9
  • Agilent Technologies Singapore (Holdings) Pte. Ltd. Singapore9
  • Agilent Technologies Singapore (International) Pte. Ltd. Singapore9
  • Agilent Technologies Singapore Corporation Pte. Ltd. Singapore9
  • Agilent Technologies World Trade, Inc. Delaware9
  • BioVectra Inc. Canada9
  • Dako Denmark ApS Denmark9

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Acquisitions

  1. Jul 11, 2019Acquired BioTek (company)1
  2. Mar 6, 2018Acquired Advanced Analytical Technologies (United States)1
  3. May 2010Acquired Varian, Inc.1
  4. Apr 6, 2007Stratagene California became a subsidiary1

Employees over time

  • 202317,6711

Former names

  • AGILENT TECHNOLOGIES INCNov 12, 1999 to Sep 16, 20197

Timeline

  1. Sep 8, 20268-K Executive or director change; Regulation FD disclosure87
  2. Aug 26, 20268-K Results of operations88
  3. Jun 25, 20268-K Entered a material agreement; New debt or obligation89
  4. May 27, 20268-K Results of operations; Executive or director change90
  5. May 4, 20268-K Executive or director change; Regulation FD disclosure91
  6. Apr 6, 20268-K Executive or director change92
  7. Apr 3, 20268-K Change in control93
  8. Mar 20, 20268-K Bylaws or fiscal year changed; Shareholder vote94
  9. Mar 6, 20268-K Executive or director change95
  10. Feb 25, 20268-K Results of operations96
  11. Nov 24, 20258-K Results of operations97
  12. Oct 27, 20258-K Executive or director change98
  13. May 1, 2024New chief executive Padraig McDonnell becomes CEO1
  14. Mar 18, 2015New chief executive Michael R. McMullen becomes CEO1
  15. Aug 23, 2006New chief executive William P. Sullivan becomes CEO23
  16. Nov 18, 1999Went public Listed on NYSE1
  17. 1999Founded Founded1

Calendar

Coming up

  1. Nov 23, 2026Reports results for the quarter ending Oct/2026 A year earlier it reported $1.59 a share, on Nov 24, 2025.99

When it reported results

  1. Aug 26, 2026Reported quarterly or annual results88
  2. May 27, 2026Reported quarterly or annual results90
  3. Feb 25, 2026Reported quarterly or annual results96
  4. Nov 24, 2025Reported quarterly or annual results97
  5. Aug 27, 2025Reported quarterly or annual results100
  6. May 28, 2025Reported quarterly or annual results101
  7. Feb 26, 2025Reported quarterly or annual results102
  8. Nov 25, 2024Reported quarterly or annual results103

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

526 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 59 major events, 361 insider forms, 19 large holders, 67 other. The latest 20:

  1. Sep 23, 2026EFFECT EDGAR
  2. Sep 23, 2026424B3 EDGAR
  3. Sep 10, 20264 PRIMARY DOCUMENT EDGAR
  4. Sep 10, 20263 PRIMARY DOCUMENT EDGAR
  5. Sep 9, 20264 PRIMARY DOCUMENT EDGAR
  6. Sep 8, 20268-K EDGAR
  7. Sep 4, 2026144 EDGAR
  8. Sep 1, 2026S-4 EDGAR
  9. Sep 1, 2026S-3ASR EDGAR
  10. Sep 1, 202610-Q EDGAR
  11. Aug 26, 20268-K EDGAR
  12. Jun 29, 20264 PRIMARY DOCUMENT EDGAR
  13. Jun 25, 20268-K EDGAR
  14. Jun 5, 20263 PRIMARY DOCUMENT EDGAR
  15. Jun 5, 20264 PRIMARY DOCUMENT EDGAR
  16. Jun 2, 20264 PRIMARY DOCUMENT EDGAR
  17. Jun 1, 202610-Q EDGAR
  18. May 29, 2026144 EDGAR
  19. May 29, 2026SD EDGAR
  20. May 27, 20268-K EDGAR

The 526 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

63 open-market trades by officers, directors and large owners since October 2021: 2 buys and 61 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 4, 2026Dolsten MikaelDirectorSale634$151.38$96.0KForm 4
May 29, 2026Dolsten MikaelDirectorSale1,600$135.42$216.7KForm 4
Dec 1, 2025Dolsten MikaelDirectorSale2,600$149.81$389.5KForm 4
Nov 26, 2025Gonsalves RodneyV.P., Corporate ControllerSale3,000$154.99$465.0KForm 4
Nov 18, 2025MCDONNELL PADRAIGPresident and CEOSale911$143.24$130.5KForm 4
Nov 12, 2025MCDONNELL PADRAIGPresident and CEOSale12,490$150.00$1.9MForm 4
Sep 2, 2025MCDONNELL PADRAIGPresident and CEOSale2,000$124.88$249.8KForm 4
Aug 1, 2025MCDONNELL PADRAIGPresident and CEOSale2,000$113.45$226.9KForm 4
Jul 1, 2025MCDONNELL PADRAIGPresident and CEOSale1,508$117.44$177.1KForm 4
Jun 18, 2025Brown Judy LDirectorSale8$116.53$904Form 4
Mar 31, 2025Podolsky Daniel KDirectorSale1,819$116.46$211.8KForm 4
Mar 17, 2025Gonsalves RodneyV.P., Corporate ControllerSale1,908$121.98$232.7KForm 4
Mar 6, 2025Rataj Sue H.DirectorSale6,971$126.38$881.0KForm 4
Jan 21, 2025MCDONNELL PADRAIGPresident and CEOSale1,911$150.00$286.6KForm 4
Sep 27, 2024MCDONNELL PADRAIGPresident and CEOSale47$150.00$7.0KForm 4
Sep 26, 2024Grau DominiqueSenior Vice PresidentSale15,000$145.00$2.2MForm 4
Aug 22, 2024MCDONNELL PADRAIGPresident and CEOSale1,958$145.00$283.9KForm 4
Jul 26, 2024MCDONNELL PADRAIGPresident and CEOSale1,958$140.00$274.1KForm 4
Jun 18, 2024MCDONNELL PADRAIGPresident and CEOSale1,958$135.00$264.3KForm 4
Jun 10, 2024Grau DominiqueSenior Vice PresidentSale15,000$133.28$2.0MForm 4

All 63 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Padraig McDonnell$1.1M$12.8M110
2025Robert McMahon$665.0K$5.5M110
2025Simon May$635.4K$3.9M110
2025Bret DiMarco$679.8K$3.7M110
2025Angelica Riemann$591.3K$3.2M110
2025Rodney Gonsalves$513.6K$2.7M110
2024President; Chief Executive Officer$870.0K$9.0M110
2024Former Senior VicePresident;$756.7K$8.9M110
2024Senior Vice PresidentAgilent$276.9K$3.7M110
2023Former Chief Financial Officer$726.8K$4.8M110
2023President; Chief Executive Officer$606.2K$3.3M110

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.25,599,001$3.4B0.1%−303,661
Vanguard Capital Management LLC18,449,861$2.5B0.1%+68,831
Vanguard Portfolio Management LLC14,442,441$1.9B0.1%+89,759
State Street Corp12,854,230$1.7B0.1%+89,598
Massachusetts Financial Services Co /ma/10,010,867$1.4B0.4%−2,613,223
Geode Capital Management, LLC7,595,644$1.0B0.1%+73,616
Wellington Management Group Llp7,454,686$990.2M0.2%+198,253
Deutsche Bank Ag\7,008,634$931.0M0.3%+1,024,516
Bank of New York Mellon Corp5,233,964$695.2M0.1%+2,440,360
Morgan Stanley5,185,738$688.8M0.0%+236,609
Fmr LLC5,076,167$674.3M0.0%+4,159,361
Goldman Sachs Group Inc4,707,720$625.3M0.1%+1,130,072
Pictet Asset Management Holding SA4,494,311$597.0M0.6%+996,992
Norges Bank3,869,544$514.0M0.1%New
State Farm Mutual Automobile Insurance Co3,825,278$508.1M0.3%No change
Northern Trust Corp3,691,941$490.4M0.1%−8,084
Aqr Capital Management LLC3,600,560$472.4M0.2%+609,081
Invesco Ltd.2,843,253$377.7M0.0%+529,225
Troy Asset Management Ltd2,676,647$355.5M9.9%+263,415
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC2,544,780$338.0M0.1%−101,678
Nordea Investment Management Ab2,367,726$310.8M0.3%+4,427
Jpmorgan Chase & Co2,309,368$306.8M0.0%−12,135
Dimensional Fund Advisors LP2,306,655$306.4M0.1%+197,891
First Trust Advisors LP2,079,578$276.2M0.2%+1,293,526
Glenview Capital Management, LLC1,969,541$261.6M5.2%New

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

18 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Sep 23, 2025Julie JohnsonDemocratic, HouseBuy$1,001 - $15,000+21.0%Report
Sep 23, 2025Julie JohnsonDemocratic, HouseSale$1,001 - $15,000−21.0%Report
Jul 16, 2025Lisa C. McClainRepublican, HouseSale$1,001 - $15,000−28.8%Report
Jun 17, 2025Lisa C. McClainRepublican, HouseBuy$1,001 - $15,000+19.8%Report
May 15, 2025Robert P. Bresnahan, Jr.Republican, HouseBuy$1,001 - $15,000+23.2%Report
May 12, 2025Jefferson ShreveRepublican, HouseSale$15,001 - $50,000−17.3%Report
Apr 17, 2025Jefferson ShreveRepublican, HouseBuy$15,001 - $50,000+22.2%Report
Apr 8, 2025Robert P. Bresnahan, Jr.Republican, HouseSale$1,001 - $15,000−18.8%Report
Apr 1, 2025Julie JohnsonDemocratic, HousePartial sale$1,001 - $15,000−14.1%Report
Mar 13, 2025Jefferson ShreveRepublican, HouseSale$15,001 - $50,000−7.5%Report
Mar 3, 2025Julie JohnsonDemocratic, HouseSale$1,001 - $15,000−4.7%Report
May 3, 2024Tommy TubervilleRepublican, SenateSale$1,001 - $15,000+26.9%Report
Apr 5, 2024Tommy TubervilleRepublican, SenateBuy$1,001 - $15,000−28.9%Report
Oct 16, 2023Tommy TubervilleRepublican, SenatePartial sale$1,001 - $15,000+21.9%Report
Apr 3, 2023Tommy TubervilleRepublican, SenateBuy$1,001 - $15,000−62.3%Report
Apr 3, 2022Tommy TubervilleRepublican, SenateBuy$1,001 - $15,000−40.6%Report
Nov 18, 2021Peter WelchDemocratic, HouseSale$1,001 - $15,000+57.6%Report
Feb 16, 2021Peter Meijer, HouseSale$1,001 - $15,000+61.5%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Agilent Technologies is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAGILENT TECHNOLOGIES, INC.2
  • CIK0001090872
  • Employer ID (EIN)77-051877220
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company20
  • Incorporated inDelaware20
  • Fiscal year endsOctober 312
  • Industry code (SIC)3826 Laboratory Analytical Instruments2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address5301 Stevens Creek Blvd, Santa Clara, CA 950512
  • Mailing address5301 Stevens Creek Blvd, Ms 1A-Lc, P.O. Box 58059, Santa Clara, CA 95052-80592
  • Phone(408) 345-88862
  • Shares outstanding281,928,854 as of Aug 26, 202618
  • Public float$26.6B as of Apr 30, 202520
  • AuditorPricewaterhouseCoopers LLP, San Jose, California PCAOB ID 238; it also attests to the company’s internal control over financial reporting20
  • On EDGAR sinceAug 16, 19992
  • Filings2,365 in all: 4 (1,439), 8-K (310), 10-Q (81), SC 13G/A (69), 3 (59), 4/A (55), 144 (38), DEF 14A (27)2
    All 53 form types

    10-K (26), SC 13G (25), DEFA14A (23), ARS (17), 11-K (14), 424B5 (14), S-8 (13), SD (13), 424B3 (10), 5 (10), FWP (10), UPLOAD (10), 3/A (8), S-8 POS (8), S-3ASR (7), 8-K/A (6), S-1/A (6), SC TO-C (6), SC TO-I/A (6), 10-Q/A (5), CORRESP (5), PRE 14A (5), SC 13D/A (5), SC 13D (4), SC TO-T/A (3), SCHEDULE 13G/A (3), 8-A12B (2), DFAN14A (2), S-3 (2), S-3/A (2), SC TO-I (2), SCHEDULE 13G (2), 10-K/A (1), 10-K405 (1), 305B2 (1), 424B4 (1), 8-A12B/A (1), CT ORDER (1), DEFR14A (1), EFFECT (1), NO ACT (1), POS AM (1), S-1 (1), S-4 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Dec 22, 2025
    Quarterly report (10-Q) Sep 1, 2026
    Proxy statement (DEF 14A) Feb 6, 2026
    Latest 8-K (8-K) Sep 8, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.01 par valueANew York Stock Exchange

From the cover page of the 10-K filed Dec 22, 2025 (Section 12(b) of the Exchange Act).20

Risk factors and legal proceedings

The risks Agilent Technologies names in Item 1A of its 10-K filed Dec 22, 2025: 35 risks under these headings, as written.20

  • Business and Strategic Risks
  • General economic conditions may adversely affect our operating results and financial condition.
  • Our operating results and financial condition could be harmed if the markets into which we sell our products decline or do not grow as anticipated.
  • Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of operations.
  • If we do not introduce successful new products and services in a timely manner to address increased competition through frequent new product and service introductions, rapid technological changes and changing industry standards, our products and services may become obsolete, and our operating results may suffer.
  • Demand for some of our products and services depends on the capital spending policies of our customers, research and development budgets and on government funding policies.
  • Recent and dynamic government rule making and policy changes could increase our costs, affect our markets and customers and impact our results of operations.
  • Failure to adjust our purchases due to changing market conditions or failure to accurately estimate our customers' demand could adversely affect our income.
  • Our business will suffer if we are not able to retain and hire key personnel.
  • Our strategic initiatives to adjust our cost structure could have long-term adverse effects on our business, and we may not realize the operational or financial benefits from such actions.
  • Our acquisitions, strategic investments and alliances, joint ventures, exiting of businesses and divestitures may result in financial results that are different than expected.
  • The impact of consolidation and acquisitions of competitors is difficult to predict and may harm our business.
The other 24 risks
  • Public health crises may adversely impact, and pose risks to, certain elements of our business, results of operations and financial condition, the nature and extent of which are highly uncertain and unpredictable.
  • Regulatory, Legal and Compliance Risks
  • If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results, which could lead to a loss of investor confidence in our financial statements and have an adverse effect on our stock price.
  • Our customers and we are subject to various governmental regulations. Compliance with or changes in such regulations may cause us to incur significant expenses, and if we fail to maintain satisfactory compliance with certain regulations, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil or criminal penalties.
  • We are subject to extensive regulation by the Food and Drug Administration and certain similar foreign regulatory agencies, and failure to comply with such regulations could harm our reputation, business, financial condition and results of operations.
  • Some of our products are subject to particularly complex regulations such as regulations of toxic substances, and failure to comply with such regulations could harm our business.
  • Our business may suffer if we fail to comply with government contracting laws and regulations.
  • Our reputation, ability to do business and financial statements may be harmed by improper conduct by any of our employees, agents or business partners.
  • The expectations and requirements of regulators and other key stakeholders, including on corporate governance and sustainability-related matters, continue to evolve and diverge, and our ability to meet these expectations and requirements could impact our risk exposure and financial conditions.
  • Environmental contamination from past and ongoing operations could subject us to substantial liabilities.
  • We are subject to environmental laws and regulations that expose us to a number of risks and could result in significant liabilities and costs.
  • Issues in the development, deployment, and use of artificial intelligence technologies in our business operations, services and products may result in reputational harm, regulatory action, or legal liability, and any failure to adapt to such technological developments or industry trends could adversely affect the competitiveness of our business.
  • Third parties may claim that we are infringing their intellectual property, and we could suffer significant litigation or licensing expenses or be prevented from selling products or services.
  • Third parties may infringe our intellectual property, and we may suffer competitive injury or expend significant resources enforcing our rights.
  • Operational Risks
  • Our operating results may suffer if our manufacturing capacity does not match the demand for our products.
  • If we are unable to successfully manage the consolidation and streamlining of our manufacturing operations, we may not achieve desired efficiencies, and our ability to deliver products to our customers could be disrupted.
  • Dependence on contract manufacturing and outsourcing other portions of our supply chain, including logistics and third-party package delivery services, may adversely affect our ability to bring products to market and damage our reputation. Dependence on outsourced information technology and other administrative functions may impair our ability to operate effectively.
  • If we suffer a loss to our factories, facilities or distribution system due to catastrophe, our operations could be seriously harmed.
  • If we experience a significant disruption in, or breach in security of, our information technology systems, or if we fail to implement new systems and software successfully, our business could be adversely affected.
  • Financial and Tax Risks
  • Our retirement and post retirement pension plans are subject to financial market risks that could adversely affect our future results of operations and cash flows.
  • Changes in tax laws, unfavorable resolution of tax examinations, or exposure to additional tax liabilities could have a material adverse effect on our results of operations, financial condition and liquidity.
  • If tax incentives change or cease to be in effect, our income taxes could increase significantly.
  • We have outstanding debt and may incur other debt in the future, which could adversely affect our financial condition, liquidity and results of operations.
  • We cannot assure that we will continue to pay dividends on our common stock.
  • Adverse conditions in the global banking industry and credit markets may adversely impact the value of our cash investments or impair our liquidity.

Legal proceedings

We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are probable and reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.

The opening of Item 3, Legal Proceedings.20

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
    Wikidata and SEC EDGARMikael Dolsten, Board member
  69. 69
    Wikidata and SEC EDGAROtis Brawley, Board member
  70. 70
    Wikidata and SEC EDGARMala Anand, Board member
  71. 71
    Wikidata and SEC EDGARDow R. Wilson, Board member
  72. 72
    Wikidata and SEC EDGARHans Bishop, Board member
  73. 73
    Wikidata and SEC EDGARDaniel K. Podolsky, Board member
  74. 74
    Wikidata and SEC EDGARSue H. Rataj, Board member
  75. 75
    Wikidata and SEC EDGARGeorge Scangos, Board member
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
    Wikidata and SEC EDGARHeidi K. Kunz, Board member
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95
  96. 96
  97. 97
  98. 98
  99. 99
  100. 100
  101. 101
  102. 102
  103. 103
  104. 104
  105. 105
  106. 106
  107. 107
  108. 108
  109. 109
  110. 110